Olivia Vizier

While Anima has contributed to the scientific literature itself, with a growing list of peer-reviewed publications on protein synthesis monitoring and tRNA visualization, Slonim argues that relying solely on mining existing research isn’t enough.

Industry leaders reshaping the pharma world.

From a trial design perspective, we’ve tried to make these trials as familiar to stakeholders – regulators, prescribers, payors – as possible. What’s remarkable here are the qualities of the drug that we’re developing, MM120, a pharmaceutical formulation of LSD; we don’t need to do anything inconsistent with the history of psychiatric clinical trials beyond

Pharvaris is moving forward with Phase 3 clinical trials. The RAPIDe-3 study (NCT06343779) is testing an immediate-release formulation of deucrictibant, called PHVS416, as an on-demand therapy for HAE. Recruitment is ongoing at sites in the U.S., Puerto Rico, South Korea, and Germany.

Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions.

At the World AMR Congress, Recce Pharmaceuticals contributes by making strides with a synthetic compound designed to target bacterial mutations, underscoring the need for innovation in addressing antimicrobial resistance (AMR). “Our compound is entirely synthetic,” Graham said. “We started with first principles, designing a compound that remains effective with repeated use.”

This conversation features Dr Philipp Spycher, CSO and co-founder at Araris Biotech, and Dr Rebecca Boohaker, Director of Oncology at Southern Research.

Biotech company MindMed is shoring up its cash stockpile to inch its psychedelic therapies towards approval after the feds’ recent thumbs-down of using MDMA to treat post-traumatic stress disorder.

Spinogenix founder Dr Stella Sarraf joined Sky News Business Editor Ross Greenwood to discuss the ongoing groundbreaking trial.

Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency.

Aligos is developing a capsid assembly modulator, ALG-000184, as a hepatitis B treatment. The South San Francisco, California-headquartered company presented data for the therapy at the June 2024 European Association of Liver Disease (EASL) Congress in Italy.

As WHO reports a high HBV burden, Aligos Therapeutics’ CEO highlighted the potential for pharma to address unmet needs.

As the inventor of the Araris ADC Technology, Philipp has a profound background in Bioconjugation and ADCs. He was the founding CEO since the inception of Araris in 2019 securing $40M in financing from Swiss, UK, US and Korean investors and $2.5M non-dilutive financing from the Swiss Accelerator Grant (5% funding rate).

Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming to improve efficacy and minimise

The traditional approach to treating autoimmune disease has relied on ways to suppress the immune system. COUR Pharmaceuticals is developing first-in-class therapies that instead seek to reprogram the immune system to create antigen-specific tolerance. We spoke to COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy, about how the company’s immune-modifying nanoparticles

Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company

In this post-ASCO interview with CUE Biopharma chief medical officer Matteo Levisetti, Levisetti tells pharmaphorum editor-in-chief Jonah Comstock about how his company’s tumour-specific T-cell engagers could create new opportunities for cancer immunotherapies to succeed.

“It’s an encouraging and exciting time to be in psychiatry because we now have tools available, even in clinic, that show a rapid and robust clinical response, and there are more to come,”

CEO Clarke Atwell acknowledges that it’s not the first to bring topically-administered biologic therapies to the front of the eye

Claris Bio is seeking to address the need for therapies to treat corneal disease by developing recombinant human deleted hepatocyte growth factor to improve and accelerate corneal healing.

Meanwhile, Calliditas Therapeutics announced data from the proof-of-concept Phase II trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck.

Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues.

With the stakes raised, enter Kaan Certel, Omega’s new chief business officer who joined the team at the end of May, and is focused on forging new partnerships for the company.

The idea behind Aphaia Pharma is to treat metabolic disease early enough that patients don’t progress to a type 2 diabetes diagnosis.

At Tessera, we are building a broad toolkit of Gene Writers™ to therapeutically edit the genome. Our RNA Gene Writers are designed to efficiently introduce a range of genomic changes from small nucleotide substitutions to exon or gene-sized fragments using all‑RNA compositions.

Flagship and one of the companies it founded, ProFound Therapeutics, said today they’ve agreed to identify new obesity treatments in a collaboration with Pfizer.

Y-mAbs’ Lu-177-based disialoganglioside GD2-targeting program is in phase 1 for small cell lung cancer, melanoma and sarcomas to determine treatment dose, sequence and spacing.

Elixirgen Therapeutics’ Aki Ko joins Erin Harris to detail the company’s Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.

Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections.

COUR nanoparticles (CNPs) induce antigen-specific immune tolerance by harnessing the body’s peripheral immune system.